Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NV103
- Development stage
- Preclinical
- Lead developer
- NanoValent Pharmaceuticals
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**NV103** is an investigational antibody-drug conjugate nanoparticle utilizing NanoValent Pharmaceuticals' proprietary NanoMod™ platform, featuring an anti-CD99 antibody conjugated to liposomal irinotecan for targeted delivery to CD99-positive tumors. It aims to enhance efficacy and reduce systemic toxicity of irinotecan, a topoisomerase I inhibitor, by selectively accumulating in tumor cells expressing CD99, a cell surface antigen overexpressed in certain pediatric and aggressive cancers. Developed in collaboration with Children's Hospital Los Angeles, NV103 is in advanced preclinical development with GMP validation underway for IND-enabling toxicology studies to support Phase 1/2 trials, primarily targeting Ewing sarcoma but with potential expansion to hepatocellular carcinoma, leukemia, neuroendocrine tumors, glioblastoma, and acute myeloid/lymphoblastic leukemia.[1][3][4][7][11]
- Other names
- antiCD99 TNS (CD99TNS/Ir)CD99/Irinotecan nanoparticlesAntibody-conjugated irinotecan liposomal nanoparticle
02
Targets
CD99 (CD99 molecule)
Beyond the preview
Go deeper on NV103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NV103.